1100 Dexter Avenue N, Suite 100
25 articles with Immunexpress
Immunexpress Identifies and Validates Blood Transcriptomic Signatures for Discrimination of Viral and Bacterial Infections in the Emergency Department
Publication in BMC Medicine demonstrates the combination of SeptiCyte® TRIAGE and SeptiCyte® VIRUS can discriminate between bacterial and viral infections in Emergency Department patients [23-September-2020] SEATTLE , Sept. 23, 2020 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced
Immunexpress Presents Data on Clinical Validation of SeptiCyte® RAPID for Diagnosing Sepsis at e-ISICEM
Immunexpress, Inc., a medical diagnostic company focused on improving outcomes for suspected sepsis patients, announced the presentation of analytical and clinical performance data for SeptiCyte® technology in two posters at the virtual e-ISICEM, from Sept. 15-18, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 17, 2020.
Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, has been awarded a grant from the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HH
SeptiCyte® RAPID can swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients suspected of sepsis
Immunexpress Achieves ISO 13485:2016 & EN ISO 13485:2016 Quality Certification for Worldwide Commercialization of SeptiCyte® RAPID
Immunexpress, Pty Ltd & Inc. announced that it has been successfully certified according to ISO 13485:2016 & EN ISO 13485:2016, the international standard for medical device quality management systems.
Immunexpress Secures BARDA Contract for the Continued Development of SeptiCyte™ for the Rapid and Accurate Diagnosis of Sepsis
Immunexpress, Inc. today announced its partnership with the DRIVe Solving Sepsis Initiative, a collaboration in which DRIVe will contribute $744,739 of a $3.2M project for the development and commercialization of Immunexpress' SeptiCyte™ technology on the Biocartis Idylla™ platform.
Immunexpress Receives Notice of U.S. Patent Allowance for SeptiCyte™ Technology to Quantify Biomarkers
The allowance complements the Company's growing patent portfolio of gene technology in the detection of host response to sepsis
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
Design and results of clinical trials that led to FDA clearance of SeptiCyte™ LAB published in the American Journal of Respiratory and Clinical Care Medicine
Immunexpress Release: Four-Biomarker Signature Differentiates Viral And Non-Viral Causes Of Systemic Inflammation
FDA Green Lights Immunexpress ' Revolutionary Diagnostic SeptiCyte LAB for Suspected Sepsis Patients
Immunexpress Release: Septicyte LAB Outperforms Other Parameters For Distinguishing Sepsis In Data Presented At The American Thoracic Society International Conference
Immunexpress Announces Presentation At The American Thoracic Society International Conference On The Validation Of SeptiCyte Lab
Immunexpress And Academic Medical Center To Collaborate On Development Of Sepsis-Related Biomarker Panels
Immunexpress Presents On The Need For An Objective Diagnostic Tool For Systemic Inflammation At The International Symposium On Intensive Care And Emergency Medicine
Immunexpress Announces Presentation At The 36th International Symposium On Intensive Care And Emergency Medicine On The Need For An Objective Diagnostic Tool For Systemic Inflammation
Immunexpress Presents Results Indicating The Utility Of SeptiCyte For The Diagnosis Of Sepsis In Critically Ill Children At The 45th Annual Society Of Critical Care Medicine Congress
Immunexpress Announces Presentations At The 45th Annual Society Of Critical Care Medicine Congress On The Utility Of SeptiCyte Lab